Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer
Recruiting · NCT05893966 · Observational (researchers observe without assigning treatment) · Lead sponsor: Samsung Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The purpose of this study is to analyze treatment outcomes related to tumor bed boost of postoperative radiation therapy in patient with HER2+ breast cancer who underwent breast conserving surgery. The main questions it aims to answer are: * 7-year ipsilateral breast tumor recurrence * 7-year disease-free survival * 7-year locoregional recurrence * 7-year overall survival * Adverse events of radiation therapy Participants will be assessed by multi-dimensional methods after radiation therapy: * Assessment for the disease status (disease-free or recurrence) including physical and radiologic examination * Assessment for the adverse events according to CTCAE version 5.0
Who can take part
Inclusion criteria
- Female patients with age minimum 19
- Pathological confirmation of HER2+ invasive breast cancer
- Eastern Cooperative Oncology Group performance status 0-2
- Informed consent of the participant
Exclusion criteria
- Pathological confirmation of ductal carcinoma in situ of the breast
- Previous history of radiation therapy to ipsilateral breast
Where it is running
1 location listed.
- Samsung Medical Center - Seoul, Seoul, South Korea